Agios Pharmaceuticals

Historical price data

Agios Pharmaceuticals is a clinical-stage biopharma company with a singular focus on pioneering therapies for rare genetic diseases by targeting cellular metabolism. The company successfully pivoted from oncology, having discovered IDH mutations and launched two approved cancer drugs, to concentrate its resources on rare metabolic disorders following the $2 billion divestiture of its oncology portfolio to Servier. Its current strategy centers on advancing its lead asset, mitapivat, a pyruvate kinase activator, through late-stage trials for pyruvate kinase deficiency, thalassemia, and sickle cell disease, while cultivating a research engine for novel metabolic targets.

Proprietary platform leveraging deep expertise in cellular metabolism to develop small molecule therapies, with a focus on enzyme activation (e.g., pyruvate kinase) for rare genetic diseases.

Agios is first-to-market in PK deficiency with no direct late-stage competitors. In thalassemia, it faces competition from luspatercept and gene therapies, but targets an untreated patient segment. The sickle cell disease landscape is intensely competitive with multiple chronic therapies and newly approved curative gene therapies, requiring mitapivat to demonstrate clear differentiation.